论文部分内容阅读
目的探讨肿瘤石蜡组织中BRCA1基因和RAP80 mRNA表达水平与接受铂类药物化疗的胃癌患者生存时间之间的关系。方法提取福尔马林固定-石蜡包埋胃癌组织RNA,采用逆转录聚合酶链反应(RT-PCR)检测BRCA1基因和RAP80 mRNA的表达水平,比较其表达水平与接受铂类化疗患者的临床病理与生存时间之间的关系。结果 74例胃癌患者中,BRCA1 mRNA低表达患者生存时间为19.3个月,高表达患者生存时间为13.3个月(P=0.17)。RAP80 mRNA低表达患者生存时间为18.2个月,高表达患者生存时间为10.9个月(P=0.07)。BRCA1和RAP80均低表达的患者生存时间为20.3个月,均高表达的患者生存时间为9.1个月(P=0.015)。结论 BRCA1和RAP80 mRNA的表达水平可以作为以铂类为基础药物化疗的胃癌患者的生存时间的预测分子,结论需更大样本的临床研究进一步验证。
Objective To investigate the relationship between the expression of BRCA1 gene and RAP80 mRNA in paraffin-embedded tissues and the survival time of gastric cancer patients receiving platinum-based chemotherapy. Methods RNA of formalin-fixed paraffin-embedded gastric cancer tissues was extracted and the expression of BRCA1 and RAP80 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR). The expression level of BRCA1 mRNA and RAP80 mRNA was compared with that of patients receiving platinum-based chemotherapy And the relationship between the time of existence. Results The survival of patients with low expression of BRCA1 mRNA was 19.3 months in 74 patients with gastric cancer, and the survival time was 13.3 months in patients with high expression (P = 0.17). The survival time of patients with low expression of RAP80 mRNA was 18.2 months, while that of patients with high expression of RAP80 mRNA was 10.9 months (P = 0.07). The survival time of patients with low expression of BRCA1 and RAP80 was 20.3 months, and the survival time of patients with high expression of BRCA1 and RAP80 was 9.1 months (P = 0.015). Conclusion The expression levels of BRCA1 and RAP80 mRNA may be used as predictors of the survival time of patients with gastric cancer based on platinum-based drug chemotherapy. The conclusion is that further validation is needed in clinical trials of larger samples.